Head-to-head · Cost-Efficiency Index
Breeze Meds vs Aquivia Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Breeze Meds
People who want to independently verify the clinicians and pharmacy behind their GLP-1 — and who'll pay a mid-market price for that paper trail plus FSA/HSA eligibility.
Visit Breeze MedsAquivia Health
Cost-first shoppers who want clinician-reviewed compounded GLP-1 with optional branded upgrade.
Visit Aquivia HealthThe verdict
Breeze Meds takes it, leading the Cost-Efficiency Index 86 to 61. The most transparent operator in our partner tier — all-50 compounded GLP-1 with NPI-verifiable named physicians, named pharmacies and LegitScript backing, so you can actually audit who's behind the script. Aquivia Health still earns a C — Cost-first shoppers who want clinician-reviewed compounded GLP-1 with optional branded upgrade.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Breeze Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Breeze Meds | Aquivia Health |
|---|---|---|
| Cost-Efficiency Index | 86/100 | 61/100 |
| Semaglutide / mo | $199/mo | $149/mo |
| Tirzepatide / mo | $399/mo | $179/mo |
| Semaglutide / yr (modeled) | $2,388 | $1,788 |
| Tirzepatide / yr (modeled) | $4,788 | $2,148 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Yes |
| Rank on the board | #5 | #219 |
Breeze Meds
86/100Where the value is
- Best transparency of this partner batch — NPI-verifiable named physicians (Lion MD group), named dispensing pharmacies, and LegitScript certification
- All 50 states, with injectable semaglutide from $199/mo plus oral semaglutide (~$299) and oral tirzepatide (~$399) for the needle-averse
- FSA/HSA eligible, which trims the effective monthly cost
The tradeoffs
- Mid-to-higher per-month pricing — tirzepatide and the oral routes carry a premium over the cheapest all-50 rivals
- Compounded only — not FDA-approved brand-name medication
Aquivia Health
61/100Where the value is
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
The tradeoffs
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.